



BETA DRUGS LIMITED

BDL/PKL/SEC/2021
1st May, 2021

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Bandra East
Mumbai 400051

Script :-BETA

Sub: Disclosure pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

Response or Submission in the context of clarification sought by Exchange - NSE EMERGE vide mail dated 29th April 2021.

Dear Sir,

We acknowledge the receipt of your e-mail dated 29th April, 2021, seeking clarification for the statement of audited financial results for the half year/ year ended 31st March, 2021, submitted to Exchange - NSE EMERGE, on its approval by the Board of Directors at its meeting held on Tuesday, the 27th April 2021 and have duly noted the contents thereof.

As desired vide the subjected communication, kindly treat following note as a part of the notes to the accounts for the half year/year ended on 31st March 2021 as submitted on 27th April, 2021:

"The above results for the half year ended 31st March, 2021 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2021 and the published unaudited year to date figure of the first half of the financial year."

Kindly treat the aforesaid submission as due compliance of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

You are therefore, kindly requested to take note of the same and oblige.

Thanking You
Yours faithfully
For Beta Drugs Ltd.


Rajni Brar
Company Secretary

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com